Relevant BNF section: BNF 220.127.116.11
Several drugs that act on the incretin hormonal system are now licensed in the UK as add-on therapy for patients with type 2 diabetes mellitus and inadequate glycaemic control.1 ▼Liraglutide (Victoza – Novo Nordisk) is a recently licensed long-acting glucagon-like peptide-1 (GLP-1) mimetic that can be given once daily as a subcutaneous injection, as part of either dual or triple therapy.2 Advertising claims that use of the drug leads to “reductions in weight”; “reductions in systolic blood pressure”; and “improvements in β-cell function”, as well as reductions in blood glucose concentrations. Here we assess the evidence for these claims and consider whether liraglutide has a role in the management of patients with type 2 diabetes.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.